Czech Republic has retained its top position and has extended its lead over second placed Poland

New Market Study Published: Czech Republic Pharmaceuticals & Healthcare Report Q4 2010

– In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings for Q410, the Czech Republic has retained its top position and has extended its lead over second placed Poland. The long-term outlook for pharmaceutical sales has improved since Q310, mainly as a result of the healthier macroeconomic indicators. BMI has revised up the 2010 real GDP growth forecast to 2.7%, from 2.2% previously, as the Czech Republic continues to enjoy robust exports data on account of a improving German economy. The compound annual growth rate (CAGR) for Czech drug market expenditure now stands at 6.05% in local currency terms and 6.98% in US dollar terms between 2009 and 2014.

The combination of a concurrent high Rewards score, which positions the Czech Republic second only to Russia in this category, and a superior Risks score – behind only Slovenia and Estonia – are weighted and combined to deliver the Czech Republic’s top position in the Pharmaceuticals & Healthcare Business Environment Ratings for Q410.

The Czech Republic’s pharmaceutical market grew by 9.0% in local currency terms in 2009 to CZK79.16bn (US$4.16bn) at consumer prices. Based on the improved macroeconomic data and early figures from the State Institute for Drug Control (SUKL), our Q410 forecast for 2010 drug expenditure has improved moderately to 7.1% growth to CZK84.80bn (US$4.30bn), compared to 6.2% growth forecast in the Q310 report.

Following the legislative election in May 2010, the outlook for healthcare and the potential for reforms were examined by BMI. The new centre-right coalition’s plans for the healthcare sector in the Czech Republic are generally favourable in terms of financial sustainability and the positive implications for the healthcare and pharmaceutical industries. However, BMI remains concerned that the strength of the healthcare reform programme is dependent on the delivery of a more comprehensive and exhaustive budget plan, as well as definitive actions to deliver the planned reforms.

Government departments face budget cuts of 10% from 2011 but the treasury has ring fenced health insurance contributions. Healthcare is viewed as a major priority for the government, with extensive reform programmes expected in the medical services sector and the pensions system.

On the macroeconomic front, growth is expected to slow in 2011 as the government pursues fiscal austerity and export growth moderates. While we regard the government’s austerity drive as positive for the Czech Republic’s long-term macroeconomic stability, it will undoubtedly be a drag on headline growth due to lower government consumption and the depressing effect this will have on private consumption growth.

For more information or to purchase this report, go to:

–  http://www.fastmr.com/prod/89916_czech_republic_pharmace …

Report Table of Contents:

Executive Summary

SWOT Analysis

– Czech Republic Pharmaceuticals And Healthcare Industry SWOT

– Czech Republic Political SWOT

– Czech Republic Economic SWOT

– Czech Republic Business Environment SWOT

Pharmaceutical Business Environment Ratings

– Table: Emerging Europe Pharmaceuticals Business Environment Ratings, Q410

– Rewards

– Risks

Czech Republic – Market Summary

Regulatory Regime

– Regulatory Developments

– Pharmaceutical Advertising

– Intellectual Property Environment

– Pricing And Reimbursement Regime

– Pricing And Reimbursement Developments

– Table: Price Changes For Select Ratiopharm Products

– Prescribing Rules

Industry Developments

– Epidemiology

– Healthcare Sector

– Healthcare Sector Financing

– Healthcare Insurance

– Healthcare Reforms

– Hospital Sector

– Opposition To Health Fees

– Pharmaceutical Wholesale

– Pharmaceutical Retail

– Table: Retail Pharmacy Market, 2000-2008

– E-Pharmacies

– Distance Selling Of Pharmaceuticals

– Medical Devices

Industry Forecast Scenario

– Overall Market Forecast

– Key Growth Factors – Industry

– Key Growth Factors – Macroeconomic

– Table: Czech Republic Economic Activity, 2005-2014

– Prescription Drug Market Forecast

– Patented Product Market Forecast

– Generic Drug Market Forecast

– OTC Medicine Market Forecast

– Medical Device Market Forecast

– Pharmaceutical Trade Forecast

– Other Healthcare Data Forecasts

– Key Risks To BMI’s Forecast Scenario

Competitive Landscape

– Pharmaceutical Sector

– Company Developments

– Research & Development Sector

– Biotechnology

Company Monitor

– Indigenous Companies

– Zentiva (Sanofi-Aventis)

– Walmark

– Multinational Companies

– AstraZeneca

– Bristol-Myers Squibb

– Sanofi-Aventis

– Novartis

– GlaxoSmithKline

– Pfizer

Country Snapshot: Czech Republic Demographic Data

– Section 1: Population

– Table: Demographic Indicators, 2005-2030

– Table: Rural/Urban Breakdown, 2005-2030

– Section 2: Education And Healthcare

– Table: Education, 2002-2005

– Table: Vital Statistics, 2005-2030

– Section 3: Labour Market And Spending Power

– Table: Employment Indicators, 2001-2006

– Table: Consumer Expenditure, 2000-2012 (US$)

– Table: Average Annual Wages, 2000-2012

BMI Methodology

– How We Generate Our Pharmaceutical Industry Forecasts

– Risk/Reward Ratings Methodology

– Ratings Overview

– Table: Pharmaceutical Business Environment Indicators

– Weighting

– Table: Weighting Of Components

– Sources

Forecast Tables

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI’s country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world’s top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #